TOI - NASDAQ
The Oncology Institute, Inc.
$4.23
-7.8%The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
At a Glance
Live SnapshotThe Oncology Institute, Inc. Management Team
Mr. Richard Alan Barasch
Chairman of the Board
Mr. Jordan McInerney
Chief Development Officer
Dr. Daniel Virnich FACHE, M.B.A., M.D.
Chief Executive Officer & Executive Director
Compensation
$704,251
Mr. Robert Carter
Chief Financial Officer
Dr. Yale D. Podnos F.A.C.S., M.D., M.P.H.
Chief Medical Officer
Compensation
$573,764
Mr. Jeremy N. Castle M.B.A.
Chief Operations Officer
Compensation
$475,950
Mr. Mark Hueppelsheuser Esq.
General Counsel
Mr. Stephen Cella
Senior Vice President of Finance
Mr. Austin Lee
Vice President of Accounting & Controller
The Oncology Institute, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.28M and sold $3.63M worth of TOI shares, resulting in $1.35M of net selling activity.
3 Months
714.9K
2.28M
95.7K
335.13K
+1.9M
+$1.94M
3-6 Months
0
0.00
13.6K
51.17K
-51K
-$51K
6-9 Months
0
0.00
2.2K
8.64K
-9K
-$9K
9-12 Months
0
0.00
1.5M
3.24M
-3.2M
-$3.24M
Top Buyers
Chernett Jorey
10 Percent Owner
$2.28M
Top Sellers
M33 Growth I L.P.
Director, 10 Percent Owner:
$2.34M
Barasch Richard A
Director
$814K
Kaushal Mohit
Director
$335K
Hively Brad
Director
$132K
Pacala Mark L
Director
$9K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $1.35M net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
TOI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 17, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 27, 2025 | May 07, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | May 02, 2024 | June 13, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 15, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | June 03, 2022 | July 14, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.